Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults who have been diagnosed with, or are suspected of having, myelodysplastic syndrome (a type of blood/bone marrow disorder) at the time of diagnosis or during ongoing monitoring
- People whose care is managed at the Cancer-Hematology Institute of Brest CHRU (a specific hospital centre in France)
- People who have biological samples (such as blood or tissue) already stored in the hospital's biological resource centre (CRB)
- People who have given their consent to participate in the trial
Who may not be able to join:
- People who are under 18 years old, or who are pregnant
- People who do not have biological samples stored in the hospital's biological resource centre (CRB)
- People who have refused to participate, have not given consent, or are unable to give consent
- People who are under a form of legal protection or guardianship (for example, under court-appointed guardianship or curatorship) (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Nathalie Douet-Guilbert, MD,PhD, CHRU BREST
Phone: +33229020215
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Cohort MDS: epidemiologic MSD study
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.